Pharma Commercialization—Thought Leader Interview Series

Pharma Commercialization—Thought Leader Interview Series With Doug Fulling, Precision AQ

In this Q&A with Doug Fulling (President of Precision AQ), we discuss the company’s rebrand, the critical role value and access plays in the pharma commercialization lifecycle, and other factors that are transforming the industry.

Pharma Commercialization—Thought Leader Interview Series With Lucid Group

In this Q&A, we discuss Lucid Group’s early engagement with HCPs, the impact of FDA approval slowdowns in 2022, the evolution of the pharma commercialization industry landscape, and more.

Pharma Commercialization—Thought Leader Interview Series With OPEN Health

In this Q&A, we discuss key industry trends around the growing demand for Market Access and HEOR capabilities, the rapidly evolving trend-line in Medical Affairs budgets, the importance of elevated engagement across the patient community, and how OPEN Health’s medical expertise and global reach continue to drive differentiation.

Pharma Commercialization—Thought Leader Interview Series With The Lockwood Group

In this Q&A, we discuss The Lockwood Group's early engagement with HCPs during the pre-approval process, the impact of FDA approval slowdowns, the evolution of the industry landscape, and more.